Journal article
Standardizing biomarker testing for Canadian patients with advanced lung cancer
Abstract
BACKGROUND: The development and approval of both targeted and immune therapies for patients with advanced non-small cell lung cancer (nsclc) has significantly improved patient survival rates and quality of life. Biomarker testing for patients newly diagnosed with nsclc, as well as for patients progressing after treatment with epidermal growth factor receptor (EGFR) inhibitors, is the standard of care in Canada and many parts of the world.
Authors
Melosky B; Blais N; Cheema P; Couture C; Juergens R; Kamel-Reid S; Tsao M-S; Wheatley-Price P; Xu Z; Ionescu DN
Journal
Current Oncology, Vol. 25, No. 1, pp. 73–82
Publisher
MDPI
Publication Date
February 2018
DOI
10.3747/co.25.3867
ISSN
1198-0052